KSP-1007 is a new bicyclic boronate-based broad-spectrum β-lactamase inhibitor that, in combination with meropenem, is under development for the treatment of infections caused by carbapenem-resistant gram-negative bacteria that produce serine- and metallo-type carbapenemases.

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award Arrepath Inc. $3.7 million to execute a lead optimization workplan for its first-in-class antibiotic targeting a clinically novel target for the treatment of complicated urinary tract infections caused by multidrug-resistant Enterobacterales.